| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/28/2006 | CA2602328A1 Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications |
| 09/28/2006 | CA2602324A1 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer |
| 09/28/2006 | CA2602294A1 Heterobicylic inhibitors of hvc |
| 09/28/2006 | CA2602241A1 Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments |
| 09/28/2006 | CA2602236A1 Use of amino-substituted benzimidazoles |
| 09/28/2006 | CA2602233A1 Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments |
| 09/28/2006 | CA2602229A1 Substituted, bicyclic 8-pyrrolidino-benzimidazoles, method for their production and their use as medicaments |
| 09/28/2006 | CA2602224A1 Polymorphic form of 6- (4-chlorophenyl) -2, 2-dimethyl-7-phenyl-2, 3-dihydro-lh-pyrrolizin-5-ylacetic acid |
| 09/28/2006 | CA2602210A1 Tablet-type controlled-release preparation containing cinnarizine and dimenhydrinate for combating vertigo |
| 09/28/2006 | CA2602209A1 Pellet-type controlled-release preparation containing cinnarizine and dimenhydrinate for combating vertigo |
| 09/28/2006 | CA2602208A1 Addition salts of tolperisone, processes for their preparation and use thereof |
| 09/28/2006 | CA2602194A1 Substituted oxindol derivatives, drugs containing said derivatives and the use thereof |
| 09/28/2006 | CA2602174A1 Substituted oxindole derivatives, medicaments containing the latter and use thereof |
| 09/28/2006 | CA2602151A1 Piperidinyl substituted cyclohexane-1,4-diamines |
| 09/28/2006 | CA2602140A1 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| 09/28/2006 | CA2602112A1 Sulfonyl containing compounds as cysteine protease inhibitors |
| 09/28/2006 | CA2602099A1 Methods for treating or preventing acute myelogenous leukemia |
| 09/28/2006 | CA2602097A1 Process for producing carbapenem derivatives having 1-alkylpyrrolidine structure |
| 09/28/2006 | CA2602017A1 A topical composition and its uses |
| 09/28/2006 | CA2602003A1 Process for the preparation of 2-azabicyclo[3.3.0]octane-3-carboxylic acid derivatives |
| 09/28/2006 | CA2602000A1 Solid oral dosage form of valopi citabine (val-mcyd) and method of preparing it |
| 09/28/2006 | CA2601914A1 20-alkyl, gemini vitamin d3 compounds and methods of use thereof |
| 09/28/2006 | CA2601907A1 Methods of treating skin and mucosal tissue atrophy using compositions including tensioning polymers |
| 09/28/2006 | CA2601895A1 Amino acid composition for improving glucose tolerance |
| 09/28/2006 | CA2601873A1 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| 09/28/2006 | CA2601871A1 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| 09/28/2006 | CA2601855A1 Inhibitor of peroxisome proliferator-activated receptor alpha coactivator 1 |
| 09/28/2006 | CA2601795A1 Chewing gum compositions of varenicline |
| 09/28/2006 | CA2601766A1 N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| 09/28/2006 | CA2601709A1 Beta-lactamylalkanoic acids for treating premenstrual disorders |
| 09/28/2006 | CA2601641A1 Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin |
| 09/28/2006 | CA2601640A1 Use of macrolides for treating intestinal inflammation |
| 09/28/2006 | CA2601545A1 Use of vitamin d compounds to treat endometriosis |
| 09/28/2006 | CA2601523A1 Novel thiophene sulfoximines for treating complement-mediated diseases and conditions |
| 09/28/2006 | CA2601509A1 Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions |
| 09/28/2006 | CA2601424A1 Substituted oxindole derivatives, medicaments containing the latter and use thereof |
| 09/28/2006 | CA2601401A1 Novel polymorph form g of fluvastatin sodium and process for the preparation thereof |
| 09/28/2006 | CA2601388A1 Thioamide-substituted tricyclic benzimidazoles useful for the treatment of gastrointestinal diseases |
| 09/28/2006 | CA2601381A1 6-thioamide substituted benzimidazoles |
| 09/28/2006 | CA2601377A1 Reduction of postoperative pain medication |
| 09/28/2006 | CA2601373A1 Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
| 09/28/2006 | CA2601363A1 Nanoparticulate biphosphonate compositions |
| 09/28/2006 | CA2601312A1 Injectable compositions of nanoparticulate immunosuppressive compounds |
| 09/28/2006 | CA2601135A1 Synthesis of avrainvillamide, stephacidin b, and analogues thereof |
| 09/28/2006 | CA2601000A1 Arylsulfonyl benzofused heterocycles as 5-ht2a antagonists |
| 09/28/2006 | CA2600773A1 Benzamidine derivatives for treatment and prevention of cancer therapy induced mucositis |
| 09/28/2006 | CA2600759A1 1,2,4-triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors |
| 09/28/2006 | CA2600757A1 Pyrrolidine derivatives as histamine h3 receptor antagonists |
| 09/28/2006 | CA2600576A1 Method for the protection of trees comprising treatment with a macrocyclic lactone |
| 09/28/2006 | CA2600550A1 Composition and method for modulating hydrogen ion physiology |
| 09/28/2006 | CA2600533A1 Pharmaceutical composition |
| 09/28/2006 | CA2600531A1 Pyrimidine compounds and methods of use |
| 09/28/2006 | CA2600478A1 Imidazopyridazine compounds |
| 09/28/2006 | CA2600189A1 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists |
| 09/28/2006 | CA2600144A1 Compounds and compositions as protein kinase inhibitors |
| 09/28/2006 | CA2600074A1 Novel cyclic aminophenylalkanoic acid derivative |
| 09/28/2006 | CA2600063A1 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension |
| 09/28/2006 | CA2599855A1 1-benzylindole-2-carboxamide derivatives |
| 09/28/2006 | CA2599794A1 Cinnamoyl compound and use thereof |
| 09/28/2006 | CA2599436A1 Mitotic kinesin inhibitors |
| 09/28/2006 | CA2599390A1 Mitotic kinesin inhibitors |
| 09/28/2006 | CA2599018A1 Methods and systems for operating an aerosol generator |
| 09/28/2006 | CA2598589A1 11-beta-hydroxysteroid dehydrogenase inhibitors |
| 09/28/2006 | CA2598205A1 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
| 09/28/2006 | CA2598134A1 Ultra low strength electric field network-mediated ex vivo gene, protein and drug delivery in cells |
| 09/28/2006 | CA2597700A1 Dosing regimes for trans-clomiphene |
| 09/28/2006 | CA2597688A1 Agglomerated starch compositions |
| 09/28/2006 | CA2587183A1 Andrographolide derivatives to treat viral infections |
| 09/28/2006 | CA2580857A1 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| 09/27/2006 | EP1705246A1 Glycerophosphoinositol as a stabilizer and / or preservative of biological materials |
| 09/27/2006 | EP1705192A1 New chondroitin fractions and their use as a medicament |
| 09/27/2006 | EP1705184A1 Treatment of neoplastic diseases using a combination of plasminogen activators and sulfhydryl donors |
| 09/27/2006 | EP1705179A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 09/27/2006 | EP1705177A1 N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
| 09/27/2006 | EP1705176A1 Carboxamide derivative and use thereof |
| 09/27/2006 | EP1705174A1 Selective androgen receptor modulators and methods of use thereof |
| 09/27/2006 | EP1705169A2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 09/27/2006 | EP1704870A1 Use of iron compounds as radiosensitizers |
| 09/27/2006 | EP1704865A2 Treatment of C. difficile toxin B associated conditions |
| 09/27/2006 | EP1704864A2 Process for producing an injectable pharmaceutical preparation |
| 09/27/2006 | EP1704863A2 Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent |
| 09/27/2006 | EP1704862A1 2,5-bis(tetrahydroxybutyl)pyrazines for the treatment of osteoarthritis and rheumatoid arthritis |
| 09/27/2006 | EP1704861A1 Lipase inhibitor |
| 09/27/2006 | EP1704860A1 Benzamidine derivatives for treatment and prevention of mucositis |
| 09/27/2006 | EP1704859A1 Androgen receptor-dependent gene expression control by inhibiting the amine oxidase activity of lysine-specific demethylase (LSD1) |
| 09/27/2006 | EP1704858A1 Propofol-containing fat emulsion preparation |
| 09/27/2006 | EP1704857A1 Abca1 stabilizer |
| 09/27/2006 | EP1704856A1 Hsp90 family protein inhibitor |
| 09/27/2006 | EP1704855A2 2-Cyclopenten-1-one and its Derivatives as Inhibitors of the NF-kappa B Factor |
| 09/27/2006 | EP1704250A2 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 09/27/2006 | EP1704243A2 Oligonucleotide compound and method for treating nidovirus infections |
| 09/27/2006 | EP1704231A2 Ppmp as a ceramide catabolism inhibitor for cancer treatment |
| 09/27/2006 | EP1704225A2 Wound dressing and method for controlling severe, life-threatening bleeding |
| 09/27/2006 | EP1704186A2 Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases |
| 09/27/2006 | EP1704166A2 M-csf-specific monoclonal antibody and uses thereof |
| 09/27/2006 | EP1704162A1 Method for producing 1,2-unsaturated azasteroids |
| 09/27/2006 | EP1704161A1 Helix 12 directed steroidal pharmaceutical products |
| 09/27/2006 | EP1704155A1 Sphingomyelin, intermediates thereof and methods for preparation of same |
| 09/27/2006 | EP1704152A2 Crystalline clopidogrel hydrobromide and processes for preparation thereof |
| 09/27/2006 | EP1704151A1 Multi-nuclear metal complexes partially encapsulated by cucurbit[7-12] urils |